MedCloud Minute
The MedCloud Minute blog is researched, fact-checked, edited and updated by the editors of MedCloudInsider.com, with writing assistance from AI. To submit your company's press release for consideration, contact [email protected].
Astrin Biosciences, a cancer intelligence company, has established a scientific advisory board to support the development of its AI-enabled proteomics platform for early cancer detection. The new board includes clinicians and researchers with backgrounds in oncology, biomarker discovery and machine learning, who will advise on study design, validation strategies and clinical translation. The development of the board comes post the launch of Astrin's Certitude Breast, a non-imaging screening test that can detect breast cancer in early stages. Astrin claims expert input is critical as it advances toward larger trials and potential regulatory pathways.
More
Posted by MedCloudInsider Editors on 12/08/20250 comments
Inductive Bio, an AI drug discovery partner, has received an award of up to $21 million to advance AI-driven toxicity models intended to improve drug safety assessment and reduce downstream development risk. The company will work with leading academic and biopharmaceutical partners to generate datasets, validate predictive models and evaluate how AI can better characterize off-target effects early in the R&D cycle. Inductive Bio aims to use the initiative to address persistent gaps in preclinical toxicity screening, where conventional models often fail to capture complex biological interactions that later lead to trial delays or program termination.
More
Posted by MedCloudInsider Editors on 12/08/20250 comments
ALR Technologies, a data management company, plans to relaunch its GluCurve Pet Continuous Glucose Monitor (CGM) in January 2026. The device is designed to help veterinarians and pet owners monitor glucose levels in diabetic cats and dogs through continuous, automated readings rather than periodic manual tests. Blood sugar readings are uploaded to the ALRT Veterinary Web Portal so that vets can easily monitor readings and adjust insulin levels accordingly for their patients.
More
Posted by MedCloudInsider Editors on 12/08/20250 comments
CaliberMRI, an automation software and imaging phantoms company, has introduced the qDisc, a new quantitative MRI phantom designed to augment the functionality of the Medium ACR Phantom commonly used in clinical quality-assurance workflows. The qDisc provides stable reference materials for diffusion, T1/T2 relaxation and temperature measurements, allowing imaging teams to perform more comprehensive scanner performance checks without adding complex new equipment. The company says the device provides a practical option to gather metrics during routine scans. The harmonization of MRI scanners and AI software for analysis can be done using the qDisc, which complements CaliberMRI's existing offerings.
More
Posted by MedCloudInsider Editors on 12/01/20250 comments
Hoppr and Ferrum Health, an AI-insights service provider, have announced a partnership to launch a full foundation-model development suite designed specifically for healthcare organizations. The platform will allow hospitals, research centers and developers to build or fine-tune large medical AI models using their own imaging and clinical datasets while keeping all data within a secure, compliance-focused environment. The integrated suite offers development tooling, data curation, model training, evaluation frameworks, interoperability and seamless deployment into Ferrum's governance layer.
More
Posted by MedCloudInsider Editors on 12/01/20250 comments
ScreenPoint Medical, an AI-powered technological company specializing in breast imaging to help detect breast cancer, showcased new advancements to its Transpara Breast AI Suite at RSNA 2025. The updated suite provides risk scoring, lesion detection and triage tools designed to help radiologists prioritize cases and identify cancers earlier, particularly in dense breast tissue. The company noted that Transpara is already in clinical use in more than 30 countries and is designed to integrate with existing PACS and reading workflows without major process changes.
More
Posted by MedCloudInsider Editors on 12/01/20250 comments
Hoth Therapeutics, a clinical-stage biopharmaceutical company, has been accepted into the NVIDIA Connect Program, providing the company with access to NVIDIA’s accelerated computing and AI development resources. Hoth plans to use these tools to speed computational modeling, data processing, and target evaluation across its early-stage pipeline, which includes programs in dermatology, inflammation, and oncology. The company said the program will support both internal research and collaborations by enabling larger-scale simulations and AI-driven analysis. The connection provides Hoth Therapeutics with GPU-accelerated developer tools, SDKs and APIs as well as co-marketing for increased visibility.
More
Posted by MedCloudInsider Editors on 11/24/20250 comments
Aperture Therapeutics, a preclinical biotechnology company, has announced a new development candidate targeting CD33, a receptor implicated in dysfunctional microglial activity in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The therapy is designed to restore microglial homeostasis by modulating CD33 signaling, which research shows can reduce harmful inflammatory responses and improve debris clearance in the central nervous system. The company reports that preclinical work supports CD33 as a viable path toward slowing or modifying disease progression, and the candidate will advance into IND-enabling studies.
More
Posted by MedCloudInsider Editors on 11/24/20250 comments
Citius Oncology plans to integrate Verix AI into the commercial launch of LYMPHIR, its recently approved IL-2 receptor–directed fusion protein for adults with persistent or recurrent cutaneous T-cell lymphoma (CTCL). Verix AI will support real-world patient identification, streamline specialty distribution workflows, and provide field teams with coordinated insights for clinician engagement. Citius says the platform is intended to improve speed-to-treatment in a rare cancer where diagnosis is often delayed and access pathways can be complex.
More
Posted by MedCloudInsider Editors on 11/24/20250 comments
Rapid Nexus, a medical device company, has become the first to receive FDA clearance for an advanced wound-healing gel device designed to support early-stage tissue recovery. The device, Hemastyl, uses a proprietary formulation and applicator system intended for use in emergency medicine, surgery and outpatient wound care. According to the company, Hemastyl can quickly stop bleeding while creating an environment that promotes faster healing and reduces complication risks—key needs in trauma and chronic wound settings.
More
Posted by MedCloudInsider Editors on 11/17/20250 comments
Lunit, an AI for cancer diagnostics provider and Labcorp, an innovative laboratory service provider, have announced a strategic collaboration to expand AI-powered digital pathology research, combining Labcorp’s large-scale tissue datasets with Lunit’s AI models for slide interpretation. The partnership will focus on improving biomarker discovery, refining diagnostic accuracy and supporting translational research in oncology. Lunit’s algorithms will be applied to Labcorp’s scanned pathology slides to analyze tumor microenvironments, quantify biomarkers and identify patterns that may guide treatment selection. The companies say the work will support both early-stage research and future clinical study design.
More
Posted by MedCloudInsider Editors on 11/17/20250 comments
Leucid Bio, a biotechnology company dedicated to the development of cell therapies, has shared an update from its ongoing Phase I/IIa AERIAL clinical trial evaluating LEU011, a Lateral CAR-T therapy targeting NKG2D ligands in advanced solid tumors. Interim results show sustained partial responses and evidence of immune persistence in patients with recurrent or metastatic head and neck squamous cell carcinoma. The treatment demonstrated a manageable safety profile with no new dose-limiting toxicities.
More
Posted by MedCloudInsider Editors on 11/10/20250 comments